Introduction
The recognition of antigen by CD4 ϩ helper T cells requires that peptide fragments derived from the antigen be bound to MHC class II molecules and the resulting complexes displayed on the surface of antigen-presenting cells (APC) (reviewed in 1). The assembly of antigenic peptide-class II complexes occurs in subcellular compartments of the endocytic system where newly synthesized class II molecules meet antigen internalized from outside the cell. Although a fairly detailed picture is emerging of the biosynthesis of the class II molecules (reviewed in 2) and the subcellular compartments in which processed antigen-class II complexes assemble (3), the intracellular trafficking of the components of the from proteins destined for secretion or expression on the cell surface at the trans-Golgi network (TGN) (9, 10) . Surface expressed proteins rapidly move to the plasma membrane (PM) and the class II molecules traffic to antigen-processing compartments.
The subcellular compartments in which processed antigenclass II complexes form and the trafficking of Ii-class II complexes to these compartments have been recently characterized (reviewed in 3). The results from several groups indicate that a major site for the assembly of functional processed antigen-class II complexes is a dense lysosomelike compartment termed the MIIC by Peters et al. (10) and referred to here as the class II peptide-loading compartment (IIPLC). In addition to the IIPLC, low-density, early endocytic, class II-containing compartments have also been implicated as sites of antigen processing (11) (12) (13) , suggesting that antigen-processing compartments may be heterogeneous. The IIPLC contains additional components necessary for the assembly of peptide-class II complexes, including the proteases cathepsin D and B required for the proteolytic removal of Ii from the class II molecules (10, 14, 15) , and DM, a class II-like molecule which catalyzes the binding of peptides to class II molecules (16) (17) (18) . Current ultrastructural and biochemical evidence indicates that the majority of Ii-class II complexes are transported from the TGN directly to the IIPLC (19) (20) (21) . However, the detection of Ii-class II complexes transiently at the cell surface in other studies (13, 22) suggested that the delivery of class II molecules to the IIPLC could involve transport to the cell surface and subsequent retrieval to the IIPLC. Recent evidence indicates that only a minority of class II molecules are transported via the cell surface to processing compartments and that the majority of Ii-class II complexes are targeted directly to the IIPLC from the TGN (20) . Once the Ii-class II complexes reach the peptide-loading compartment, the Ii is rapidly, proteolytically degraded (14, 18, 19, 23) , resulting in complexes of class II molecules filled with a nested set of Ii peptides, residues 81-104, called CLIP for class II-associated Ii peptides (24) . The final step in the assembly process involves the DM-mediated dissociation of CLIP from the class II peptide binding groove and the binding of antigenic peptides (reviewed in 25) .
At present, little is known about the cellular and molecular machinery required for trafficking of the Ii-class II complexes and other components of the IIPLC in the endocytic system. Moreover, it is not known if all components necessary for antigen-processing traffic to the IIPLC via the same pathway or if multiple pathways are involved. Recently, phosphatidylinositol-3-kinases (PI3-kinases) have been implicated to play an essential role in the trafficking of proteins from the TGN to endosomes and lysosomes (reviewed in 26). The PI3-kinases are a family of lipid kinases which are found associated with a variety of cell surface receptors involved in diverse cellular processes. PI3-kinase activity can be found in virtually all cell types, and regulates a variety of responses including chemotaxis, mitogenesis and the oxidative burst response in neutrophils (reviewed in 27). The first indication of a role for PI3-kinases in membrane trafficking came from the demonstration in Saccharomyces cerevisiae that the VPS34 gene, whose product is required for the correct transport of soluble hydrolases from the TGN to the yeast vacuole, the equivalent of the mammalian lysosome, was a PI3-kinase (28) . Subsequently, evidence was provided for a role for PI3-kinases in the mannose-6 phosphate receptor (M6PR)-dependent transport of the protease cathepsin D, from the TGN to lysosomes in mammalian cells (29, 30) .
At present, our understanding of the diversity and functions of the PI3-kinases is still evolving. There are at least three families of PI3-kinases with different substrate specificities and relative sensitivities to the fungal metabolite, wortmannin (reviewed in 26). PI3-kinases linked to receptors with intrinsic tyrosine kinase activity show a substrate specificity for phosphatidylinositol (PtdIns), PtdIns 4-phosphate [PtdIns(4)P] and PtdIns (4,5)-biphosphate [PtdIns(4,5)P 2 ], and are sensitive to wortmannin in the nanomolar range. A second class of PI3-kinases are G protein activated and may represent a distinct family. A third class, which includes the yeast Vps34p PI3-kinase, is restricted to PtdIns as a substrate and is relatively insensitive to wortmannin in vitro, requiring micromolar concentrations. It is not clear that wortmannin insensitivity will be a general feature of this type of PI3-kinase as a human PI3-kinase, related to the yeast Vps34p kinase, has been cloned recently and is highly sensitive to wortmannin in vitro (31) . Clearly, there is still a great deal to learn about the PI3-kinases and their function in mammalian cells. Here we explore the possible role of PI3-kinases in the class II antigenprocessing pathway, using the PI3-kinase inhibitor wortmannin, and provide evidence for a role for PI3-kinases in at least one route from the TGN to the antigen-processing compartments in B cells. These observations have interesting implications for the mechanisms by which the assembly of processed antigen-class II complexes may be regulated in B cells.
Methods

Materials
The PI3-kinase inhibitor, wortmannin, and the cysteine proteinase inhibitor, leupeptin, were obtained from Sigma (St Louis, MO). Stock solutions were prepared in DMSO for wortmannin (10 mM) and leupeptin (20 mg/ml). Concanamycin A was purchased from Sigma. A 50 µM stock solution of concanamycin A was prepared in DMSO.
Antigens, cell lines and antibodies
Pigeon cytochrome c (Pc) was prepared as described (32) and when indicated was covalently coupled to affinity-purified rabbit antibodies specific for mouse Ig (Pc-anti-Ig), as detailed elsewhere (33) . A peptide representing the C-terminus of tobacco hornworm moth c (THMc) residues 81-103 (THMc 81-103) was synthesized as described (34) . CH27 is a mouse B cell lymphoma which is IgM ϩ , FcR -, E kϩ (35) . TPc 9.1 is a mouse Pc-specific E k -restricted T cell hybrid which shows a high-affinity cross-reactivity with THMc 81-103 (36) . CTLL-2 is an IL-2-dependent T cell line (37) . The human B lymphoblastoid cell line, .114, was isolated and kindly provided by Dr R. DeMars (University of Wisconsin, Madison, WI) (38) . All cell lines were grown in complete media which is Dulbecco's modified Eagle's media supplemented as described (39) . The mouse hybridoma 17.3.3s producing an I-E k -specific mAb (40) was obtained from ATCC (Rockville, MD). IN-1, a mAb-producing hybridoma specific for the N-terminal cytoplasmic tail of Ii, was kindly provided by Dr N. Koch (Immunobiology Zoologisches Institute Universitat, Bonn, Germany). A rabbit polyclonal antiserum recognizing all forms of human cathepsin D was obtained from Dako (High Wycombe, UK).
APC assay
CH27 cells were pulsed with antigens in the presence of graded doses of wortmannin (1-10 µM) for various periods of time. At the end of each time point, the cells were washed, fixed in 0.1% glutaraldehyde as described (41) and incubated in graded numbers with TPc 9.1 cells. The IL-2 content of the culture supernatants was determined 24 h later by the ability to maintain the growth of the IL-2-dependent CTLL-2 cell line, as measured by the incorporation of [ 3 H]thymidine (42) . Alternatively, CH27 cells were treated with wortmannin, fixed, and co-cultured with graded concentrations of peptide, THMc 81-108 and TPc 9.1 cells for 24 h, and the IL-2 content of the supernatants were measured.
Subcellular fractionation
Subcellular fractionation was conducted as detailed elsewhere (19) using 2ϫ10 8 cells per Percoll gradient. Twentytwo 0.5 ml fractions were collected and pooled as described (19) 6 ) were removed, washed, lysed and immunoprecipitations were carried out.
Surface biotinylation
CH27 cells were washed at 4°C with Hank's balanced salt solution lacking phosphate and containing 20 mM Na HEPES, pH 7.4, and incubated in the same buffer containing 0.2 mg/ml sulfosuccinimidyl-6-(biotinamido)hexanoate (Pierce, Rockford, IL) for 15 min at 4°C. The same volume of biotin solution was added and the incubation was extended for another 15 min at 4°C. The cells were washed with DME-BSA (0.6 mg BSA/ml) to quench the reaction.
PI3-kinase enzyme assays
Assays were performed in a total volume of 50 µl. The reaction buffer contained 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 3.5 mM MnCl 2 , 100 µg/ml PtdIns (Sigma) and 300 µg/ml phosphatidylserine (Sigma) (31) . The phospholipids were sonicated in the reaction buffer for 30 s on ice to form lipid vesicles. An aliquot of the pooled fraction (10 µl) was incubated with 35 µl of the reaction buffer alone or in the presence of increasing concentrations of wortmannin as indicated, for 10 min at room temperature. The reaction was started by the addition of 5 µl of ATP at a final concentration of 50 µM containing 10 µCi [γ-32 P]ATP (3000 mCi/mmol) per sample. The assay mixture was incubated for another 10 min at room temperature. The reaction was stopped by the addition of 100 µl of 1 N HCl and lipids were extracted with 200 µl of chloroform:methanol (2:1, v/v). Phase separation was accelerated by centrifugation and the upper phase discarded and the lower, organic phase was washed twice with 400 µl of methanol:1 N HCl (1:1, v/v) and dried under nitrogen. The lipids were dissolved with 15 µl chloroform and analyzed by TLC. TLC plates (Merck Silica gel 60; Aldrich, Milwaukee, WI) were sprayed with 1% (g/v) potassium oxalate, 1 mM EDTA in methanol:water (40:60) and activated at 120°C for 30 min. TLC was run in propan-1-ol:2 M acetic acid (65:35) (43) . The products of PI3-kinase reactions were separated by TLC and identified by autoradiography, and quantified by phosphor imaging and scintillation counting. The 32 P-labeled products which co-migrated with authentic phosphatidylinositol phosphate (PIP) (Sigma) were scraped from the plates and deacylated by incubation in the presence of 1 ml methanol:40% methylamine:n-butanol (4:4:1) at 56°C for 45 min (43) . After drying under vacuum, glycero-PIP (gPIP) pellets were suspended in 0.5 ml H 2 O, clarified by centrifugation and extracted twice with butanol:petroleum ether:ethyl formate (20:4:1). Samples were then dried under vacuum and stored at -20°C.
HPLC separation of glycerophosphoinositides
Deacylated PIP preparations were analyzed by anion exchange HPLC using a Whatman Partisphere 5-SAX column (44) . The HPLC system consisted of two independent pumps [A pumped H 2 O, B pumped 0.3125 M (NH 4 ) 2 HPO 4 adjusted to pH 3.8 with H 3 PO 4 ], a digital controller, a mixing device and a 1.0 ml injection loop. Samples (in 0.5 ml of H 2 O) were injected as the chromatography system was pumping solution A at 1 ml/min. Immediately after injection, the following linear elution gradient was initiated: 1 min to 8% B, 19 min to 12% B, 24 min to 100% B, 29 min to 100% B and 30 min to 0% B. Fractions (0.5 ml) were collected directly into scintillation vials and Cerenkov radioactivity in each fraction was measured using a Beckman LS 6000 scintillation counter. Samples were counted for 5 min to minimize error and values obtained were corrected for background emissions. Under these HPLC conditions, 32 P-labeled gPI(3)P and gPI(4)P consistently eluted 16 and 20 min after injection of sample respectively, coincident with authentic standards prepared from cells metabolically labeled with myo-[ 3 H]inositol (45) .
Results
Wortmannin, a PI3-kinase inhibitor, blocks antigen processing
We examined the effect of wortmannin on the processing of a model protein antigen, Pc, by the B cell lymphoma, CH27. The processing and presentation of three different forms of the antigen was tested: soluble Pc, taken up by B cells via fluid phase pinocytosis; Pc covalently coupled to antibodies specific for mouse Ig (Pc-anti-Ig) which enters the B cell by binding to the B cell antigen receptor (BCR); and a peptide fragment of the cross-reactive cytochrome c from tobacco hornworm moth (THMc) residues 81-103, which contains the T cell antigenic determinant but does not require processing (46). CH27 cells were incubated with the antigens and wortmannin for various lengths of time, washed fixed, and assayed for their APC function. Wortmannin blocked the processing and presentation of all three antigens in a dosedependent fashion (Fig. 1A-C) . APC are first able to stimulate an antigen-specific T cell hybrid after 3-4 h of incubation with the antigens and at this time presentation is blocked by wortmannin. The effect of wortmannin on antigen processing and presentation was fully reversible, even at the highest dose used (10 µM) (Fig. 2) .
Although wortmannin severely limited the processing of both Pc and Pc-anti-Ig, it appeared to have a greater effect on the processing of Pc-anti-Ig as compared to Pc, possibly reflecting a selective effect of wortmannin on BCR-mediated processing. Wortmannin also prevented the presentation of the peptide antigen THMc 81-103 that is not dependent on intracellular processing. It is not known if the mechanism by which wortmannin blocks exogenous peptide presentation is the same as the mechanism by which wortmannin blocks processing of native antigens. In the experiment shown in Fig. 1(C) , the cells were incubated with peptide in the presence of wortmannin, washed and fixed. Thus, wortmannin effects the ability of live cells to assemble peptide-class II complexes. We further explored the effect of wortmannin on peptide presentation and tested whether wortmannin-treated fixed APC were able to present peptide. We found that wortmannin decreased peptide presentation but only at the highest dose (10 µM) and the inhibition achieved was only 45% of untreated cells (Fig. 1D ). Thus, wortmannin had a more significant effect on the ability of live versus fixed APC to present exogenous peptide. This suggests that wortmannin may have an effect on an intracellular process important for peptide presentation in live cells, not required for presentation by fixed cells. Lastly, the effect of wortmannin on peptide presentation was not due to leakage of wortmannin from treated cells into the culture supernatant because co-culturing wortmannin-treated cells with untreated cells in the APC assay did not diminish peptide presentation by untreated cells (Fig.  1E ). In fact, the cultures containing wortmannin-treated fixed APC in addition to unfixed APC showed higher levels of T cell activation.
The association of PI3-kinase activity with subcellular fractions containing the IIPLC
The observation that wortmannin blocked antigen processing suggested a possible role for PI3-kinases in membrane trafficking in the antigen-processing pathway. To explore this possibility, we examined the PI3-kinase activity associated with the IIPLC of the CH27 cells. Cells were homogenized and the subcellular organelles separated by centrifugation on Percoll density gradients. Previous studies using a variety of enzymatic, serological and functional markers identified the position of various subcellular compartments in the gradient (18, 47) . Using these markers, the Percoll density gradient fractions were pooled as follows: pool 1 (fractions 2-4) containing early and late endosomes and Golgi; pool 2 (fractions 6-8) containing late endosomes, PM and ER; pool 3 (fractions 13-15) containing transport vesicles; and pool 4 (fractions [20] [21] [22] containing the IIPLC and lysosomes. PI3-kinase assays were carried out on pool 4 using PtdIns as a substrate and detecting the product PtdIns(3)P, as detailed in Methods. Pool 4 contained PI3-kinase activity, as evidenced by the phosphorylation of PtdIns to produce PtdIns(3)P (Fig.  3B) . The PI3-kinase activity was highly sensitive to wortmannin in vitro with complete inhibition achieved at the lowest concentrations of wortmannin used (5 nM).
The dose of wortmannin required for inhibition of the PI3-kinase activity associated with the subcellular fractions containing the IIPLC in vitro was lower than that required for inhibition of B cell APC activity in vivo. We considered that the relative insensitivity of antigen processing to wortmannin may be due to a number of factors including the permeability of the CH27 cells to wortmannin or the subcellular microenvironment of the IIPLC where the kinase may function. To explore the effect of wortmannin on the PI3-kinase activity associated with the IIPLC in vivo, cells were treated with varying concentrations of wortmannin for 4 h at 37°C, subjected to subcellular fractionation and the subcellular fractions assayed for PI3-kinase activity. We first determined whether wortmannin altered the distribution of the subcellular organelles in the density gradients. Percoll gradient fractions derived from wortmannin-treated and untreated cells were assayed for markers of Golgi (α-mannosidase II) and late endosomes and lysosomes (β-hexosaminidase). The distribution of these two enzymes was not altered significantly in the wortmannin-treated cells as compared to untreated cells (Fig.  4) . The α-mannosidase II activity was somewhat less in fractions 1-3 in wortmannin-treated versus untreated cells; however, this difference was within the variability of measurements of enzymatic activity from one gradient to another.
Treatment of cells with 1 µM wortmannin blocked the PI3-kinase activity associated pool 4 containing the IIPLC tõ 30% of the control. A complete block in the PI3-kinase activity associated with the IIPLC required treatment of the cells with 10 µM wortmannin (Fig. 3A) . This is in contrast to the 5 nM concentration of wortmannin required to completely block the IIPLC associated PI3-kinase activity in vitro. Thus, the PI3-kinase activity associated with the IIPLC appears to be relatively insensitive to wortmannin in vivo, correlating with the dose of wortmannin required to block APC function.
Wortmannin inhibits the formation of SDS-stable class II molecules
To further explore the mechanism by which wortmannin treatment blocked APC function, the effect of wortmannin on the assembly of processed antigen class II complexes was investigated. The α and β chains of the class II molecules form heterodimers which in the absence of bound peptides are unstable and dissociate in SDS (48) (49) (50) . Upon peptide binding most αβ dimers become SDS-stable and, thus, the SDS stability of the αβ dimer provides a good biochemical measure of peptide binding. Pulse-chase experiments indicated that in the absence of wortmannin, SDS-stable class II dimers begin to appear at 1 h of chase time and by 2 h of chase time, the majority of the class II molecules are in the SDS-stable form (Fig. 5A ). Wortmannin significantly blocked Fig. 3 . PI3-kinase activity is associated with the subcellular fractions containing the IIPLC. (A) CH27 cells were cultured in media containing graded concentrations of wortmannin for 4 h at 37°C and subjected to subcellular fractionation as described (47) . Pool 4 containing the IIPLC was assayed for PI3-kinase activity as described in Methods. PI3-kinase activity is given as a percent of the activity measured in the untreated control. (B) CH27 cells were homogenized and subjected to subcellular fractionation. Aliquots of pool 4 were incubated with graded concentrations of wortmannin in vitro and assayed for PI3-kinase activity.
the formation of the SDS-stable dimers in a dose-dependent fashion. After 2 h of chase in the presence of 10 µM wortmannin, nearly all the class II molecules are SDS-unstable and migrate as 30 kDa chains. Although wortmannin inhibited the formation of SDS-stable dimers, it did not appear to affect the synthesis of class II molecules, since the amount of class II in the wortmannin-treated and untreated cells was similar, as quantified by phosphor imaging (data not shown). A similar inhibitory effect of wortmannin on the formation of SDS-stable αβ dimers was observed in the human B lymphoblastoid cell line, .114 (data not shown).
The effect of wortmannin on the assembly of peptideclass II complexes was reversible (Fig. 5B) . Pulse-chase experiments were carried out in the presence of wortmannin and wortmannin was removed at various times during the chase period. In untreated control cells, SDS-stable dimers were detected following 1 h of chase time and increased by 2 h (Fig. 5B) . In the continual presence of wortmannin (Fig.  5B, panel a) , very few class II molecules form SDS-stable dimers as compared to the untreated control. The removal of wortmannin either in the beginning of the chase period (Fig.   Fig. 4 . Distribution of subcellular organelles from wortmannin-treated cells in Percoll density gradients. CH27 cells were incubated in the absence (open symbols) or presence of wortmannin (10 µM) (closed symbols) for 4 h and subjected to subcellular fractionation as previously described (47) . Gradient fractions were assayed for β-hexosaminadase, a marker for late endosome/lysosomes, and α-mannosidase II, a Golgi marker. The enzyme activity is represented as the percent of total activity measured in all fractions.
5B, panel b) or after 1 h of chase (Fig. 5B, panel c) resulted in the formation of SDS-stable class II dimers within 2 h. The affect of wortmannin is not completely reversible, indicating that not all Ii-class II complexes which accumulate in wortmannin-treated cells can mature into SDS-stable molecules upon removal of wortmannin. Thus, wortmannin blocks the formation of SDS-stable dimers and the formation of dimers can be restored partially after removal of wortmannin.
Wortmannin decreases the degradation of Ii
An essential prerequisite for the loading of class II molecules with peptides to generate SDS-stable αβ heterodimers is the removal of Ii from the class II molecules by proteolysis (51) . We investigated whether wortmannin treatment affects the degradation of Ii. We compared wortmannin to the cysteine proteinase inhibitor, leupeptin, which blocks complete degradation of Ii, resulting in fragments of Ii associated with class II molecules (15, 51, 52) . Class II-associated Ii was detected in [ 35 S]Met-labeled cells by sequential immunoprecipitation. In leupeptin-treated cells there was a dramatic accumulation of Ii-class II complexes and complexes of class II molecules with a 12 kDa fragment of Ii called SLIP, for small leupeptin-induced fragments of Ii (Fig. 6) . The accumulation of Ii-class II complexes was greater in wortmannin-treated cells as compared to leupeptin-treated cells, whereas the amount of SLIP-class II complexes was more in leupeptintreated cells as compared to wortmannin-treated cells. These data indicate a more complete block of Ii proteolysis following wortmannin treatment as compared to leupeptin treatment. Treatment with a combination of wortmannin and leupeptin resulted in an even greater accumulation of Ii and a reduction in the amount of SLIP-class II complexes as compared to treatment with either inhibitor alone, suggesting that in the presence of leupeptin, wortmannin prevents the proteolysis of Ii to yield SLIP. Thus, cells treated with wortmannin appear to be significantly impaired in their ability to degrade class II-associated Ii which in turn contributes to the failure to form SDS-unstable dimers.
The subcellular distribution of Ii and class II molecules in wortmannin-treated cells
The effect of wortmannin on Ii degradation and formation of SDS-stable dimers may reflect the mistargeting of Ii-class II complexes from the TGN to the peptide-loading compartment. Alternatively, the trafficking of Ii-class II complexes to the peptide-loading compartment may proceed normally in wortmannin-treated cells but wortmannin may block the trafficking of other essential components necessary for the assembly of Met for 4 h in the absence of inhibitors or in the presence of either leupeptin (400 µg/ml) or wortmannin (10 µM) or a combination of leupeptin plus wortmannin. Class IIassociated Ii was detected by sequential immunoprecipitations. Cell lysates were first immunoprecipitated using the class II-specific mAb 17.3.3s and the class II precipitates were reprecipitated using the Iispecific mAb IN-1. The final immunoprecipitates were analyzed by Tris-Tricine gel electrophoresis and radiolabeled proteins were detected by fluorography (19) . A representative autoradiograph of three individual experiments is shown.
class II molecules. To explore these possibilities, we tested the effect of wortmannin on the subcellular distribution of Ii and class II molecules. CH27, cells metabolically labeled in the presence or absence of wortmannin, were subjected to subcellular fractionation by Percoll density gradient centrifugation. As shown in Fig. 4 , wortmannin treatment did not significantly alter the distribution of subcellular organelles in the density gradients. The subcellular distribution of class II molecules and Ii was also not significantly affected by wortmannin treatment. In untreated cells, SDS-stable class II dimers were found in the fractions containing the PM (pool 2) and the IIPLC (pool 4) (Fig. 7A and B) . A small amount of Ii and SDS-unstable class II molecules was immunoprecipitated from the PM/ER-containing fractions (pool 2) which likely represents newly synthesized Ii-class II complexes in the ER. In wortmannin-treated cells, the pattern was similar, although no SDS-stable class II molecules were detected and there was an increase in the total amount of Ii (Fig. 7A and B) . Significantly, a similar percentage of the class II molecules in wortmannin-treated cells was present in the dense fractions containing the IIPLC. We also analyzed the subcellular distribution of class II-associated Ii by sequential immunoprecipitation and found that although wortmannin treatment resulted in an increase in Ii-class II complexes, it did not alter distribution of the complexes (data not shown). Thus, wortmannin does not block the transport of Ii-class II complexes to subcellular fractions containing the IIPLC.
The observation that the Ii and class II molecules in both wortmannin-treated and untreated cells reside in the subcellular fractions which contain the IIPLC does not rule out the possibility that the Ii-class II arrived in this compartment via different pathways. To follow the movement of class II molecules to the IIPLC, pulse-chase experiments were carried out in conjunction with subcellular fractionation. The results showed that as soon as compacted SDS-stable class II molecules are detected in the pool 4 of untreated cells, after 1 h of chase, class II molecules are detected in pool 4 derived from wortmannin-treated cells (Fig. 8A and B) . After a 2 h chase, the class II molecules continued to accumulate in pool 4 in treated and untreated cells. These results indicate that wortmannin does not significantly alter the intracellular trafficking of the class II molecules to processing compartments. There are, however, some differences in transport in treated and untreated cells. In wortmannin-treated cells, the rate of accumulation in pool 4 is slowed somewhat and more class II molecules are found in pool 3, which previous studies showed contains transport vesicles moving Ii-class II complexes from the TGN to the IIPLC (19) . This backing up of the class II molecules under conditions where Ii does not dissociate from class II molecules was previously observed in leupeptin-treated cells (19) . It is possible that if the class II molecules are unable to assemble properly and exit the IIPLC, then import of Ii-class II molecules to the IIPLC from the TGN is slowed.
Wortmannin has been shown to cause the mistargeting of proteins transported by the M6PR from the TGN to lysosomes in fibroblast, resulting in their secretion from cells (29, 30) . If the Ii-class II complexes are transported via the M6PR route, we would predict that wortmannin treatment would result in mistargeting of Ii-class II complexes to the PM. The analysis of the subcellular distribution of class II and Ii molecules over a 4 h period of continuous labeling did not indicate any significant change in the amount of either class II or Ii in the PM-containing fractions (see Fig. 7A and B) . Moreover, the pulse-chase experiment did not indicate a diversion of the Ii-class II complexes to the PM (see Fig. 8A and B) . In addition, flow cytometric analyses of surface class II and Ii using fluorescent labeled mAb specific for class II and Ii showed no significant change in the surface expression of either Ii or class II in wortmannin-treated versus untreated cells (data not shown).
To further investigate the expression of newly synthesized class II molecules and Ii on the PM in wortmannin-treated cells, cells were metabolically labeled for 4 h, and then surface biotinylated and subjected to sequential immunoprecipitation to detect biotinylated Ii and class II molecules. Thus, in this experiment, only the newly synthesized class II and Ii molecules which appear on the cell surface over a 4 h period will be detected. This represents a small portion of the total class II and Ii molecules present in the cell and on the cell surface. The effect of wortmannin was compared to that of leupeptin which blocks Ii degradation. In wortmannin-treated cells, there was a consistent increase in the amount of newly synthesized class II molecules on the PM over 4 h, representing an increase of~50% over untreated cells and leupeptin-treated cells (Fig. 9A and C) . However, the number of newly synthesized class II molecules detected on the surface is not large enough to account for the mistargeting to the PM of all the class II molecules synthesized over a 4 h period. Wortmannin treatment also resulted in an increase in the amount of newly synthesized Ii expressed on the surface over a 4 h period ( Fig. 9A and C) . The amount of Ii expressed on the cell surface in untreated cells is a small portion of the total cellular Ii and the increase observed in wortmannintreated cells does not account for all the Ii synthesized in the cell over a 4 h period. The increase in Ii on the cell surface may also be partially accounted for by the effect of wortmannin on Ii degradation. Indeed, Ii increases on the surface in leupeptin-treated cells ( Fig. 9A and C) . These results indicate that wortmannin does not result in a significant accumulation on the cell surface of Ii or class II molecules synthesized over a 4 h period. However, it is possible that wortmannin blocks the transport of Ii-class II complexes from the TGN to the IIPLC resulting in trafficking to the PM followed by rapid retrieval of the complexes to the IIPLC. We reasoned that if this were the case, then blocking retrieval in wortmannin-treated cells should result in the accumulation of all newly synthesized Ii-class II complexes on the PM. Benaroch et al. (20) showed recently that the vacuolar H ϩ ATPase inhibitor concanamycin B blocked the retrieval of Ii-class II complexes from the PM to late endosomal compartments resulting in an accumulation measured at 24 h of Ii-class II complexes on the PM. CH27 cells were treated with wortmannin in the presence or absence of concanamycin and the amount of newly synthesized Ii-class II complexes on the cell surface was measured after 1 and 4 h of labeling. As shown above, after 1 h, the Ii-class II complexes in untreated cells will have reached the IIPLC but will not yet have trafficked in the PM and after 4 h the majority of class II molecules will have reached the PM (see Fig. 8A and B). The effect of concanamycin was compared to that of ammonium chloride, a lysomotropic agent which also alters vacuolar pH. The results indicated that treatment with wortmannin and concanamycin or ammonium chloride, as compared to treatment with wortmannin alone, caused no significant change in the amount of newly synthesized Iiclass II complexes on the cell surface after 1 or 4 h (Fig. 9B  and D) . In addition, Ii was localized to subcellular fractions containing the IIPLC in cells treated with wortmannin and concanamycin (data not shown). Taken together, these results indicate that wortmannin does not result in a mistargeting of newly synthesized Ii-class II complexes from the TGN to the PM.
The effect of wortmannin on the maturation and targeting of cathepsin D
Recent studies showed that wortmannin treatment of fibroblasts blocked the processing and delivery of newly synthesized cathepsin D to lysosomes (29, 30) . As a result, cathepsin D was secreted from the wortmannin-treated cells. To determine if wortmannin had a similar effect in the B cells, We also analyzed the subcellular distribution of cathepsin D in wortmannin-treated and untreated cells (Fig. 10B) . In untreated cells, the pro form was found in most regions of the gradient, reflecting its presence in the ER, Golgi, transport vesicles and lysosomes. The intermediate form was present in light fractions which contain late endosomes and in the most dense vesicles containing the IIPLC and lysosomes. The mature form was present only in the dense compartments. The material present in the immunoprecipitates of fractions 2 
Discussion
The processing and presentation of antigen in the context of class II molecules requires the intersection of all of the components necessary for the assembly of peptide-class II complexes in the IIPLC. These components include newly synthesized Ii-class II complexes as well as the proteases necessary for the removal of Ii from class II molecules and degradation of antigens. Recently, using both immunoelectron microscopy and subcellular fractionation, progress was made in identifying and characterizing the subcellular compartments in which peptide-class II complexes assemble. Several groups, including our own, described peptide-loading compartments, which we refer to as IIPLC, that have many characteristics of lysosomes (reviewed in 3). It appears that Ii-class II complexes can be transported directly from the TGN to the IIPLC (10, (19) (20) (21) . Early ultrastructural evidence was interpreted as supporting a direct route of trafficking of class II molecules from the TGN to the processing compartments (10) . We showed that Ii-class II complexes are trafficked intact from the TGN to the IIPLC in vesicles that co-sedimented with rab9 ϩ vesicles, a small GTPase that plays a role in the delivery of enzymes to lysosomes (19) . Using the vacuolar H ϩ -ATPase inhibitor, concanamycin B, to block early to late endosomal transport, Benaroch et al. (20) showed that the majority of Ii-class II complexes traffic directly from the TGN to the IIPLC. At present, little is known about the TGN to IIPLC pathway or the cellular and molecular machinery required for appropriate trafficking.
Here we used an inhibitor of PI3-kinase, wortmannin, as a tool to further dissect the pathway of class II molecules and other processing components to the IIPLC and to explore the possible role of PI3-kinases in this pathway. By genetic analyses, PI3-kinase was first shown to be involved in membrane trafficking between the late Golgi and the yeast vacuole, the equivalent of the mammalian lysosome (28) . Subsequent studies by Davidson (29) and Brown et al. (30) showed that wortmannin caused the mistargeting of cathepsin D, resulting in its secretion from fibroblasts, providing strong evidence that PI3-kinases play a role in regulating the trafficking of the lysosomal enzyme cathepsin D in the M6PR pathway from the TGN to lysosomes in mammalian cells. The results presented here indicated that the subcellular distribution of Ii and class II molecules was not appreciably altered in wortmannin-treated cells. Significantly, in wortmannin-treated cells, Ii and class II molecules trafficked to dense fractions of Percoll gradients containing the IIPLC, indicating that Iiclass II complexes traffic to the IIPLC via a route which is independent of the M6PR pathway to the endocytic system.
Wortmannin caused an increase in the amount of newly synthesized Ii-class II complexes on the cell surface over a 4 h period. Benaroch et al. (20) earlier showed that~10% of newly synthesized Ii-class II complexes normally escape direct targeting to the processing compartments and are trafficked to the cell surface. The increase in newly synthesized Ii-class II complexes observed at the PM could reflect an effect of wortmannin on the retrieval or recycling of these complexes. Such an effect of wortmannin would presumably be independent of the effect on TGN to IIPLC transport. Indeed, wortmannin has been shown in other systems to inhibit endocytosis (56, 57) . In favor of this interpretation is the failure to observe changes in distribution of Ii in class II molecules, either in pulse-chase or during 4 h of continuous labeling, of the magnitude which would account for all the newly synthesized Ii-class II trafficking to the PM. However, it is possible that wortmannin blocked the normal trafficking of the Ii-class II complexes from the TGN to the IIPLC resulting in movement to the PM followed by rapid retrieval to the IIPLC. If this were the case, then blocking retrieval from the PM should result in an accumulation of all newly synthesized Ii-class II complexes on the cell surface. However, in cells treated with both wortmannin and concanamycin, a vacuolar H ϩ -ATPase inhibitor shown to block internalization from the PM or ammonium chloride, there was no significant increase in the expression of newly synthesized Ii-class II complexes on the cell surface as compared to wortmannin treatment alone. Taken together, these results indicate that wortmannin does not effect TGN to IIPLC transport and support a model for Ii-class II trafficking in which the majority of complexes reach the IIPLC via a route independent of M6PR trafficking to the endocytic system.
Even though the Ii-class II complexes reach the IIPLC in wortmannin-treated cells, degradation of Ii was significantly effected and the class II molecules did not bind peptide, resulting in a nearly complete block in antigen-processing function. Thus, in wortmannin-treated cells the IIPLC did not provide the proper conditions or components required for the normal degradation of Ii and the peptide loading of class II molecules. Given the previously described inhibitory effect of wortmannin on the transport of cathepsin D to the endocytic system (29, 30) , an obvious possibility was that cathepsin D, a protease required for the initial Ii degradation (14,15), was not properly targeted to the IIPLC. Indeed, we found that a portion of cathepsin D was mistargeted in B cells. In pulsechase experiments, a significant amount of cathepsin D was secreted from wortmannin-treated cells and the mature cathepsin D was not detected. In subcellular fractionation studies, the intermediate and pro forms of cathepsin D were found in the subcellular fractions which contained the IIPLC; however, no mature form was detected in these fractions, indicating that the cathepsin D which reached this compartment failed to mature. These results suggest that either cathepsin D or enzymes required for the maturation of cathepsin D are not transported to the IIPLC in wortmannin-treated cells. This would further suggest that the transport of these enzymes appears to occur independently of the transport of Ii-class II complexes to the IIPLC, indicating that there are at least two pathways to the IIPLC from the TGN.
There is substantial evidence, from studies of B cells from patients with I-cell disease (ICD), for both a M6PR-dependent and a M6PR-independent pathway for the transport of lysosomal enzymes. The M6PR-targeting mechanism is inoperative in patients with ICD, a disorder resulting in severely reduced levels of the enzyme which forms the M6PR moiety on lysosomal enzymes (58) . Consequently, most cell types have severe lysosomal enzyme deficiencies. However, B cells from ICD patients have nearly normal levels of lysosomal enzymes, which were shown to be transported via a direct intracellular route (59, 60) . In one case, cathepsin D was found to be targeted directly from the TGN to dense lysosomes by a mechanism which required specific protein recognition (60) . These findings suggested that B cells possess two separate routes of lysosomal targeting. Recent results of Glickman et al. (21) provided evidence for a link between the M6PR-independent trafficking of lysosomal enzymes in B cells and the transport of class II molecules. They showed that the majority of class II molecules are transported directly from the TGN to the peptide-loading compartment by a M6PR-independent pathway. In B cells from ICD patients, newly synthesized cathepsin D and Ii-class II complexes were observed to enter vesicles which lacked γ-adaptin, a marker for clathrin-coated vesicles. These vesicles fused with the endocytic pathway leading to the formation of peptide-loading compartments. Our findings are in agreement with these and taken together provide evidence for a M6PR-independent pathway for newly synthesized class II molecules to the peptide-loading compartment. In addition, the vesicles described by Glickman et al. (21) may be similar to the Iiclass II-containing transport vesicles we described earlier which co-sedimented with rab9 ϩ vesicles but contained no other known markers (19) .
The studies presented here also showed that even though Ii-class II transport may be independent of the M6PR pathway, the M6PR pathway or another PI3-kinase-dependent pathway must be involved in the delivery of other proteins to the IIPLC. The underlying cause of the wortmannin-induced APC deficiency was not completely delineated here. Minimally, mature cathepsin D is reduced in the peptide-loading compartment. Whether the deficiency in cathepsin D accounts for the block in antigen processing is not known. It will be of interest to determine if other components of the peptideloading compartment are also mistargeted in wortmannintreated cells. Recent studies from our laboratory showed that another essential component of the IIPLC, i.e. DM, was not mistargeted in wortmannin-treated cells and trafficks to the IIPLC (unpublished observation). This is in agreement with the observations of Copier et al. (61) indicating that HLA-DM is not transported in the same vesicles with M6PR to the endocytic system.
The target or targets of wortmannin in B lymphocytes which result in the observed effects on antigen processing, on antigen presentation, and on the targeting and maturation of cathepsin D remain to be identified. The concentration of wortmannin required to block APC function was higher than predicted based on the sensitivity of some members of the PI3-kinase family to wortmannin in vitro (reviewed in 26). PI3-kinase activity was detected associated with the IIPLC and this PI3-kinase activity was sensitive to wortmannin in vitro in the nanomolar range. However, the PI3-kinase activity associated with the IIPLC in vivo was relatively insensitive to wortmannin, requiring concentrations of wortmannin in the micromolar range, the same range as the concentrations of wortmannin required to block B cell APC function and the formation of SDS-stable class II dimers. Taken together, these results suggest a complicated picture in which the in vivo sensitivity of the PI3-kinase activity may be dictated by a number of factors. In addition, it is not known if the effect of wortmannin on processing and presentation of native antigens is the same as the effect of wortmannin on presentation of exogenous peptides. Concerning the effect of wortmannin on exogenous peptide presentation, we show that wortmannin does not significantly alter the steady-state expression of class II molecules on the cell surface as measured by FACS analysis or by subcellular fractionation and immunoprecipitation. In addition, unpublished results indicate that the turnover of biotinylated class II molecules on cell surfaces is not significantly effected by wortmannin treatment. These findings suggest that there are factors, other than the number of class II molecules on the cell surface, which influence the efficiency of exogenous peptide presentation and are sensitive to wortmannin treatment. Clearly, this is a new area in which there is still much to learn about the nature and function of the PI3-kinases in membrane transport and in the class II antigenprocessing and presentation pathway.
The possible role for PI3-kinases in the antigen-processing pathway has interesting implications for the regulation of the pathway. PI3-kinases have been primarily associated with signaling pathways involved in transducing information received through cell surface receptors. We and others have showed that signaling through certain B cell surface receptors affects the outcome of antigen processing (reviewed in 62). Recent studies provided a link between BCR signaling and biochemical changes associated with the IIPLC including changes in the profiles of phosphoproteins and small mol. wt GTPases involved in membrane trafficking (63) . Studies are in progress to explore the possibility that signaling from the cell surface may influence the trafficking of components to the IIPLC by affecting the PI3-kinase-dependent pathway.
